COPD causes 6% of the world’s morbidity and costs the worldwide economy $36 billion and though non curable, it can be tamed through a range of management mechanisms. Our 7th annual conference on
COPD will bring together respiratory leaders and scientific pioneers to strengthen knowledge in combinational therapies, new drugs and personalised treatment, whilst keeping you at the forefront of scientific breakthroughs to adapt to the growing need for efficiency in the management of exacerbations.
Understanding
COPD pulmonary indications through biomarkers and the practicalities of reliable clinical trials will be a major focus as will hearing from a selection of pharmaceutical organisations currently developing scientific trials for
COPD. This will include case studies from Novartis, Mundipharma, Janssen, MedImmune and Bayer.
Exclusive updates into formulation developments and the manufacturing of dry powder inhalation products, lymphoid follicles in
COPD and ACOS (Asthma,
COPD, Overlap Syndrome) will be just some of the conference highlights this year.
Benefits of attending:
- Discuss the advantages and disadvantages of combinational therapeutics
- Gain insight into formulation developments and the manufacturing of dry powder inhalation products
- Evaluate COPD and comorbidities
- Review the challenges in clinical trial designs and in drug development
- Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
- Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
- Explore recent advances made in COPD biomarkers
- Study the role of lymphoid follicles in COPD Novel delivery and formulation methods
- Analyse airway disease endotyping for personalized therapeutics
Plus an Interactive Half-Day Post Conference Workshop | 21st October 2015
Improving probability of success in COPD drug developmentLed by: Graham Clarke, Head of Respiratory Phase I, Quintlies Ltd. and
Juan Gispert, Senior Medical Director and Chair Centre of Excellence, Quintiles
8:30-12:30
Featured speakers Include:
- Antonio Gomez-Munoz, Professor of Biochemistry and Molecular Biology, University of the Basque Country
- Chetna Bhatia, Physical Therapist, HUG
- Corinna Schnoeller, Research Associate, Imperial College London
- Ewan Walters, Medical Director, Teva UK Ltd
- Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG
- Geoff Down, Chief Medical Officer, Prosonix Ltd
- Graham Clarke, Head of Respiratory Phase I, Quintlies Ltd.
- Jan-Anders Karlsson, CEO, Verona Pharma
- Jane Gunter, Advisor Clinical Research, Respiratory Clinical Trials
- John Hurst, Senior Clinical Lecturer, Honorary Consultant, University College London
- Juan Gispert, Senior Medical Director and Chair Centre of Excellence, Quintiles
- Konstantinos Kostikas, Medical Director Respiratory COPD Region Europe, Novartis Pharma
- Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune
- Noel Snell, Director of Research, British Lung Foundation
- Pankaj Bhavsar, Research Lecturer, Imperial College London
- Paul Lewis, Chief Scientific Officer, Glyconics
- Philip Silkoff, Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC
- Sanjeeva Dissanayake, Head of Medical Sciences – Respiratory, Mundipharma
- Stefano Petruzzelli, Chief Medical Officer and Director Global Clinical Development, Chiesi Farmaceutici S.P.A.
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Who Should Attend
Chief Executives, Chief Scientific Officers, Vice Presidents, Heads, Directors, Prinicple Scientists, Associates, Project Leaders, Specialists, and Managers in the following areas:
- Respiratory Physiology & Medicine
- Respiratory Pharmacology
- Medical Affairs
- Inflammatory Disease
- Respiratory, Inflammation and Autoimmunity
- Pulmonary Disease
- Respiratory Therapeutics
- Immunology
- Medical & Inhalation Devices
- In-Vitro Biology
- Biomarker
- Inflammation Discovery
- Preclinical R&D
- Clinical Pharmacology
- Clinical Trials
- Clinical Science
- Discovery
- Global Data Informatics
- Business Development
- Brand Manager
- Commercial
- Respiratory Licensing & Regulation
Venue
Holiday Inn Regents ParkCarburton Street
London
W1W 5EE England
